Improved Efficacy of Transcatheter Arterial Chemoembolization Using Warmed Miriplatin for Hepatocellular Carcinoma
Table 1
Profile of patients and nodules.
Nonwarmed group (n = 22)
Warmed group (n = 58)
P value
Age, years
68 (51–83)
73 (50–91)
0.086
Sex, n (%)
Male/female
17/5 (77.3/22.7%)
34/24 (58.6/41.4%)
0.10
Etiology, n (%)
0.093
HCV
14 (63.6%)
44 (75.9%)
HBV
1 (4.5%)
7 (12.1%)
Alcohol
5 (22.7%)
3 (5.2%)
Others
2 (9.2%)
4 (6.8%)
Child-Pugh, n (%)
0.73
5-6 (Class A)
13 (59.1%)
33 (56.9%)
7–9 (Class B)
8 (36.4%)
23 (39.7%)
10 (Class C)
1 (4.5%)
2 (3.4%)
Median score
6.4
6.5
BCLC stage, n (%)
0.72
0 (very early)
0 (0%)
0 (0%)
A (early)
0 (0%)
0 (0%)
B (intermediate)
8 (36.4%)
21 (36.2%)
C (advanced)
12 (54.5%)
36 (62.1%)
D (terminal)
2 (9.1%)
1 (1.7%)
PS, n (%)
0.15
0
6 (27.3%)
23 (39.7%)
1
13 (59.1%)
33 (56.9%)
2
2 (9.1%)
2 (3.4%)
3
1 (4.5%)
0 (0%)
AFP (ng/mL)
282.8 ± 723.1
415.5 ± 1454.3
0.80
DCP (mAU/mL)
1562.6 ± 5241.2
581.3 ± 2913.8
0.15
Nodule size (mm2)
388.6 ± 398.0
383.1 ± 468.0
0.72
History of TACE
18 (81.8%)
32 (55.2%)
0.038*
Agent
EPI alone
8/18 (44.4%)
4/32 (12.5%)
CDDP alone
6/18 (33.3%)
12/32 (37.5%)
MPT alone
0/18 (0%)
5/32 (15.6%)
Multiple agents
4/18 (22.3%)
11/32 (34.4%)
Number of sessions
0.087
1
11/18 (61.1%)
17/32 (53.1%)
2
4/18 (22.2%)
9/32 (28.1%)
3
1/18 (5.6%)
4/32 (12.5%)
4–6
2/18 (11.1%)
2/32 (6.3%)
Preoperative severe arterial damage
7 (31.8%)
6 (10.3%)
0.037*
Follow-up period (months)
8.5 ± 7.6 (2–36)
7.7 ± 6.0 (2–29)
0.68
≥3 months
19 (86.4%)
49 (84.5%)
1.00
≥6 months
11 (50%)
31 (53.4%)
0.81
Interval between image and TACE (months)†
0.084
<1 month
26/29 (89.7%)
62/87 (71.3%)
1-2 months
1/29 (3.4%)
18/87 (20.7%)
2-3 months
2/29 (6.9%)
7/87 (8.0%)
Age is presented as median (range). AFP, DCP, nodule size, and follow-up period are presented as mean ± standard deviation. Range of follow-up period is shown in the parentheses. P < 0.05. †Interval between preoperative image and treatment was evaluated on a per treatment session basis. HCV: hepatitis C virus; HBV: hepatitis B virus; AFP: alpha-fetoprotein; DCP: des-gamma-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; PS: performance status (Eastern Cooperative Oncology Group classification); TACE: transcatheter arterial chemoembolization; EPI: epirubicin; CDDP: cisplatin; MPT: miriplatin.